Vaccine Therapy in Treating Patients With Kidney Cancer
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent or stage III or stage IV kidney cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Kidney Cancer |
Biological: autologous tumor cell vaccine Biological: therapeutic autologous dendritic cells |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Vaccine Biotherapy Of Cancer: Autologous Tumor Cells And Dendritic Cells As Active Specific Immunotherapy In Patients With Stage IV Renal Cell Carcinoma |
- Conversion of the delayed-type hypersensitivity (DTH) skin test as measured by metric skin ruler at week 4 and month 6 during vaccine therapy [ Designated as safety issue: No ]
- Tumor response (partial response or complete response) as measured by RECIST at months 2 or 3 and 6 during study treatment, and 6 months after study completion [ Designated as safety issue: No ]
- Progression-free survival as measured by RECIST at months 2 or 3 and 6 during study treatment and every 6 months after study completion [ Designated as safety issue: No ]
- Event-free survival as measured by RECIST at months 2 or 3 and 6 during study treatment and every 6 months after study completion [ Designated as safety issue: No ]
- Overall survival beginning at the date of study entry [ Designated as safety issue: No ]
| Estimated Enrollment: | 80 |
| Study Start Date: | November 2001 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Determine the safety of immunization with in vitro-treated autologous tumor cells and dendritic cells with sargramostim (GM-CSF) in patients with stage III or IV or recurrent renal cell cancer.
- Determine the frequency of conversion of delayed tumor hypersensitivity tests in these patients treated with this regimen.
- Determine the progression-free and overall survival of these patients treated with this regimen.
- Determine the objective tumor response rate in patients who still have measurable disease at the time they are treated with this regimen.
OUTLINE: Patients are stratified according to measurable disease at the time vaccine therapy is initiated (yes vs no).
Patients undergo tumor cell harvest. Patients with multiple persistent sites of metastatic disease following harvest receive systemic therapy (biologic therapy and/or chemotherapy) during tumor cell line expansion. Over 2-4 months, the tumor cell line is expanded, treated with interferon gamma, and irradiated.
Patients undergo leukapheresis to obtain peripheral blood mononuclear cells (PBMC). The PBMC are incubated over 7 days with sargramostim (GM-CSF) and interleukin-4 to produce dendritic cells (DC). The DC are incubated over 2-3 days with the irradiated tumor cells from the autologous tumor cell line for antigen loading of the DC.
Patients undergo delayed tumor hypersensitivity testing 1 week prior to vaccination and again at week 4. Patients receive vaccine therapy comprising autologous treated tumor cells and DC suspended in GM-CSF subcutaneously weekly for 3 weeks. Vaccine therapy continues monthly for 5 months in the absence of disease progression or unacceptable toxicity.
Patients are followed every 2 months for 1 year and then every 3 months for 4 years.
PROJECTED ACCRUAL: A total of 80 patients (40 per stratum) will be accrued for this study.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed renal cell carcinoma
- Stage III or IV disease involving invasions beyond Gerota's fascia, regional lymph node involvement, or distant metastases OR
- Recurrent disease involving lymph node metastases or soft tissue nodules
- Measurable disease by anatomic-based radiological tests (unless no evidence of disease as documented by prior surgery)
- Planned resection of tumor to establish an autologous tumor cell line
No active CNS metastases such as brain metastases, spinal cord compression, or leptomeningeal disease
- Prior brain metastases or spinal cord compression allowed provided there is radiographic evidence of lack of progression and no requirement for pharmacologic doses of corticosteroids
PATIENT CHARACTERISTICS:
Age:
- 16 and over
Performance status:
- ECOG 0-2
Life expectancy:
- At least 4 months
Hematopoietic:
- Hematocrit greater than 25%
- Platelet count greater than 100,000/mm3
- No ongoing transfusion requirements
- No active blood clotting or bleeding diathesis
Hepatic:
- Bilirubin no greater than 2.0 mg/dL
- Albumin at least 3.0 g/dL
- No significant hepatic dysfunction
Renal:
- Creatinine no greater than 2.0 mg/dL
- No significant renal dysfunction
Cardiovascular:
- No underlying cardiac disease associated with New York Heart Association class III or IV heart function
- No unstable angina related to atherosclerotic cardiovascular disease
Other:
- No other malignancy within the past 5 years except carcinoma in situ, basal cell or localized squamous cell skin cancer, or localized prostate cancer
- No active infection
- No other active medical condition that could be eminently life threatening
- Not pregnant
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Other prior putative vaccines allowed
- Recovered from prior biologic therapy
- No concurrent biologic therapy except epoetin alfa for patients with hematocrit less than 36%
Chemotherapy:
- At least 3 weeks since prior chemotherapy and recovered
- No concurrent chemotherapy
Endocrine therapy:
- See Disease Characteristics
- No concurrent corticosteroids
Radiotherapy:
- At least 3 weeks since prior radiotherapy (including whole-brain radiotherapy) and recovered
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from prior surgery
Other:
- Concurrent bisphosphonates allowed for patients with lytic bone metastases
- No concurrent digoxin or other medications designed to improve cardiac output
- No other concurrent anticancer therapy or investigational therapy
Contacts and Locations| United States, California | |
| Hoag Cancer Center at Hoag Memorial Hospital Presbyterian | |
| Newport Beach, California, United States, 92663 | |
| Study Chair: | Robert O. Dillman, MD, FACP | Hoag Memorial Hospital Presbyterian |
More Information
Additional Information:
No publications provided
| Responsible Party: | Robert O. Dillman, Hoag Cancer Center at Hoag Memorial Hospital Presbyterian |
| ClinicalTrials.gov Identifier: | NCT00014131 History of Changes |
| Other Study ID Numbers: | CDR0000068493, HOAG-VACCINE-RN, NCI-V01-1647 |
| Study First Received: | April 10, 2001 |
| Last Updated: | April 7, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
stage III renal cell cancer stage IV renal cell cancer recurrent renal cell cancer |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Kidney Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013